What is the best clinical approach to recurrent/refractory osteosarcoma?

Meazza, Cristina; Bastoni, Stefano; Scanagatta, Paolo

doi:10.1080/14737140.2020.1760848

Cited by 25 publications

(18 citation statements)

References 125 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Primary and secondary bone tumors are incapacitating, painful and potentially lethal pathologies [19]. Among malignant bone neoplasms, osteosarcomas are chemo-and radio-resistant aggressive tumors, presenting a 60% survival rate and a 40% recurrence rate [20], [21]. Orthopaedic oncology is a clinical field constantly seeking patient-specific therapies to lower the recurrence rate of bone neoplasms, increase the survival rate and improving the quality of live [19]- [21].…”

Section: Introductionmentioning

confidence: 99%

“…Among malignant bone neoplasms, osteosarcomas are chemo-and radio-resistant aggressive tumors, presenting a 60% survival rate and a 40% recurrence rate [20], [21]. Orthopaedic oncology is a clinical field constantly seeking patient-specific therapies to lower the recurrence rate of bone neoplasms, increase the survival rate and improving the quality of live [19]- [21]. Currently, the gold-standard treatment strategy of bone cancers is the systemic chemotherapy, followed by surgery, i.e., curettages, osteotomies, limb sparing [21].…”

Section: Introductionmentioning

confidence: 99%

“…Orthopaedic oncology is a clinical field constantly seeking patient-specific therapies to lower the recurrence rate of bone neoplasms, increase the survival rate and improving the quality of live [19]- [21]. Currently, the gold-standard treatment strategy of bone cancers is the systemic chemotherapy, followed by surgery, i.e., curettages, osteotomies, limb sparing [21]. However, the surgical approach results in disabling outcomes and disabilities, which call for a graft, i.e., a scaffold able to improve bone healing [22], [23].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Design and Characterization of Magnetic Scaffolds for Bone Tumor Hyperthermia

et al. 2022

View full text Add to dashboard Cite

Magnetic tissue scaffolds are a promising powerful tool for performing interstitial tumor hyperthermia against the residual bone cancer cells, after surgical intervention. The design of the implant architecture is crucial for several biomedical requirements. However, to date, the influence of implant topology on the hyperthermia treatment outcome has never been assessed. Furthermore, the heating ability is a function of sample mass and geometry. In this work, a simple methodology for designing biomimetic scaffolds using triply periodic minimal surfaces is presented. A set of geometries is 3D printed by fused deposition modeling, using a commercial poly-lactic acid filament filled with magnetite particles, never tested for biomedical applications. Magnetic scaffolds were thoroughly characterized by performing static magnetic measurements, differential scanning calorimetric and thermogravimetric analysis, but, mostly, by carrying out calorimetric measurements to determine their hyperthermic potential under different experimental conditions. Numerical multiphysics simulations with a commercial finite element software were performed, resulting in good agreement with the measurements. The scaffolds were exposed to a magnetic field with 15 mT strength, working at 400 kHz, in air, and the surface temperature was recorder using infrared camera. The manufactured magnetic scaffolds can increase the temperature above 41°C (about 54-57°C), in 40-60 s. In distilled water, for a 30 mT magnetic field and 400 kHz, the temperature was recorded using an optic fiber and we observed that all the sample could be used as thermo-seed for cancer therapy. Finally, the scaffolds were tested in agarose phantoms and their hyperthermic potential was quantified.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Design and Characterization of Magnetic Scaffolds for Bone Tumor Hyperthermia

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Osteosarcoma (OS) is the most common primary malignant bone tumor that is mainly developing during childhood and adolescence 1 . Although the 5‐year survival rate of patients with OS without distant metastasis is 76%, 1 those of patients with metastases at initial diagnosis and relapsed or refractory disease remain poor—45% 1 and 13% to 40%, 2 respectively. The combination of surgical wide resection and adjuvant chemotherapy using multiple agents, such as doxorubicin, cisplatin, high‐dose methotrexate, and ifosfamide, is the standard first‐line treatment approach for high‐grade OS either with or without metastases 3 .…”

Section: Introductionmentioning

confidence: 99%

The survival and proliferation of osteosarcoma cells are dependent on the mitochondrial BIG3‐PHB2 complex formation

et al. 2021

View full text Add to dashboard Cite

Osteosarcoma (OS) is the most common primary malignant bone tumor that is mainly developing during childhood and adolescence. 1 Although the 5-year survival rate of patients with OS without distant metastasis is 76%, 1 those of patients with metastases at initial diagnosis and relapsed or refractory disease remain poor-45% 1 and 13% to 40%, 2 respectively. The combination of surgical wide resection and adjuvant chemotherapy using multiple agents, such as doxorubicin, cisplatin, high-dose methotrexate, and ifosfamide, is the standard first-line treatment approach for high-grade OS either with or without metastases. 3 For relapsed or refractory disease, although several agents and regimens, including molecular

show abstract

“…Despite advances in diagnosis and therapy, the overall prognosis of osteosarcoma patients remains poor. Moreover, recurrent metastatic osteosarcoma is observed in more than 80% of patients after surgery [ 2 , 3 ]. It is therefore urgent to identify regulators of osteosarcoma progression in order to improve therapies for this type of cancer.…”

Section: Introductionmentioning

confidence: 99%

Anoctamin 5 promotes osteosarcoma development by increasing degradation of Nel-like proteins 1 and 2

Pan¹,

Lu²,

Ren³

et al. 2021

Aging

View full text Add to dashboard Cite

Anoctamin 5 (ANO5) is a member of the Anoctamin (ANO) family of calcium-activated chloride channels. Although ANO5 expression is upregulated in various cancers, its role in osteosarcoma remains largely unknown. In this study, bioinformatics analysis, western blot, and immunohistochemical staining revealed that ANO5 was upregulated in osteosarcoma cell lines and osteosarcoma tissues, and ANO5 expression was positively associated with tumor size, tumor grade, and metastasis. Functional experiments demonstrated that inhibition of ANO5 decreased, while ANO5 overexpression increased, osteosarcoma cell proliferation and mobility in vitro . Immunoprecipitation, western blot, and confocal microscopy experiments showed that ANO5 bound to and promoted the degradation of Nel-like proteins 1 (NELL1) and 2 (NELL2). Moreover, a subcutaneous tumor transplantation model revealed that ANO5 knockdown reduced osteosarcoma cell proliferation and increased NELL1 and NELL2 expression in vivo . Finally, rescue experiments showed that knockdown of NELL1 or NELL2 reversed the inhibitory effects of ANO5 knockdown on osteosarcoma cell proliferation and migration. These results demonstrated that upregulation of ANO5 promoted osteosarcoma development by decreasing the stability of the NELL1 and NELL2 proteins and that ANO5 may be an effective target for the treatment of osteosarcoma.

show abstract

What is the best clinical approach to recurrent/refractory osteosarcoma?

Cited by 25 publications

References 125 publications

Design and Characterization of Magnetic Scaffolds for Bone Tumor Hyperthermia

Design and Characterization of Magnetic Scaffolds for Bone Tumor Hyperthermia

The survival and proliferation of osteosarcoma cells are dependent on the mitochondrial BIG3‐PHB2 complex formation

Anoctamin 5 promotes osteosarcoma development by increasing degradation of Nel-like proteins 1 and 2

Contact Info

Product

Resources

About